Diabetic Macular Edema

Diabetic retinopathy can cause swelling of the center of the retina, the macula, and vision loss.

What is a Diabetic Macular Edema

Diabetic macular edema is swelling in the retina associated with diabetes. This swelling can blur and distort the vision. The swelling occurs because the walls of the small blood vessels are progressively more damaged in diabetes, and there is leakage of blood and fluid into the cells of the retina. There are a variety of options to treat diabetic macular edema. The oldest treatment is laser for retinal swelling. It has been studied for decades and has been shown to be safe and effective. As with all treatments, it is not curative, and it is not without risk, but laser is one of the safest things that we do in diabetic retinal care. Other newer treatments for diabetic retinal swelling have been shown to improve vision even more than laser in some cases, and have also been shown to be safe and effective in large modern trials. These treatments are a variety of injections given into the eye in the office, and they are sometimes given alone and sometimes given with laser in addition. There are two major classes of injections used in diabetic macular edema, and those are small molecule injections and corticosteroid injections. The injections work in different ways to reduce the leakage and swelling in the retina, and sometimes the different types of injections are both used. The injections are administered under local anesthesia, and are often relatively well-tolerated by patients. Injections are also amongst the safest procedures performed in the retinal clinic, and the specific risks and benefits of injections will be discussed by your doctor. Most patients with blurred vision from diabetic macular edema enjoy an improvement in vision with treatment. Often, treatment to maintain vision is ongoing, and the long-term treatment plan is individualized to each specific patient in our practice.

What is a Laser?

When diabetic macular edema is caused by focal areas of leakage, laser treatment can be helpful. Studies were done in the 1980's validating the use of laser to reduce the risk of vision loss and improve vision in patients with diabetic macular edema. The advantage of laser of intravitreal injections is that laser treatment usually only needs to be repeated a few times. Intravireal injections are given monthly. The disadvantage of laser, is that it does not improve vision as much as intravitreal injections do when the center of the macula is swollen. Many physicians will use both laser and intravitreal injections depending on the area of the macula that is swollen and the findings on examination and testing.

Lucentis for Diabetic Macular Edema

Monthly Lucentis therapy is helpful for patients with diabetic macular edema. With laser only, about 15 percent of patients have substantial visual improvement at 2 years. With Lucentis therapy, about 40 percent of patients have a substantial improvement in visual acuity. Subsequent studies have shown that ongoing monthly treatment is usually not necessary to maintain the visual benefit.


Diabetic Macular Edema NEWS

Below are current articles from a Google News Feed on Diabetic Macular Edema

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema
Labiotech.eu (blog)
Results from the Phase I/II trial demonstrate the safety and tolerability of a new kind of antibody treatment for diabetic macular edema. The trial focused on injecting the THR-317 antibody, which is directed against the human placental growth factor ...
Global Diabetic Macular Edema Drug Market Analysis, Trends, Share, Forecast and Major Key Players upto 2025theaerospacenews.com

all 2 news articles »

News-Medical.net

FDA Approves Aflibercept sBLA for Wet Age-related Macular Degeneration
MD Magazine
In diabetic macular edema (DME) studies, the incidence of ATEs in the first 52 weeks was 3.3% (19 out of 578) for patients treated with aflibercept compared to 2.8% (8 out of 287) in the control group. From baseline to week 100, the incidences were 6.4 ...
FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular DegenerationPR Newswire (press release)
FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age ...Markets Insider
Eylea - Regeneron PharmaceuticalsRegeneron Pharmaceuticals

all 20 news articles »

Relationship Between Dry Retinal Volume and Visual Acuity in Diabetic Macular Edema
Healio
Eligibility criteria included: (1) foveal center-involved macular edema from diabetic retinopathy only (with no prior laser treatment), (2) baseline and follow-up volume OCT scans obtained with the same spectral-domain OCT (SD-OCT) (Cirrus HD-OCT; Carl ...


Global Diabetic Macular Edema Ongoing Clinical Trials - Analysis & Outlook to 2022 - ResearchAndMarkets.com
Business Wire (press release)
Diabetic Macular Edema ongoing clinical trials report provides comprehensive analysis and trends in global Diabetic Macular Edema disease clinical trials. The research work analyzes the ongoing Diabetic Macular Edema clinical trial trends across ...

and more »

When treating patients with age-related macular degeneration, do you perform bilateral same-day intravitreal injections?
Healio
... whenever I ask them if they prefer bilateral intravitreal injections on the same day. This is the sentiment of the vast majority of my patients with bilaterally active choroidal neovascularization or diabetic macular edema undergoing intravitreal ...


Vision problems exacerbated by diabetes
NWAOnline
According to the National Eye Institute (nei.nih.gov), an estimated 750,000 Americans have diabetic macular edema, a type of vision loss that is caused in part by too-high blood sugar levels. Macular edema is the buildup of fluid in the retina, the ...

and more »

Diabetic Macular Edema Market – Latest Trends and Future Growth Study by 2019
advertisingmarket24.com
Macular edema is the condition when the fluid and proteins start collecting on or under the macula of the eye thereby resulting in swelling. Due to such swelling, a person's central eye vision gets distorted. Macular edema is classified into two types ...


Novel antibody yields significant VA gains in DME
Healio
VANCOUVER, British Columbia — RG7716, a bispecific antibody designed for intraocular use, resulted in statistically significant visual acuity gains in patients with treatment-naive diabetic macular edema compared with anti-VEGF monotherapy, according ...


Opthea Meets Primary Safety Objective with OPT-302 in Phase 1b Diabetic Macular Edema Clinical Trial
GlobeNewswire (press release)
MELBOURNE, Australia, July 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, announced today that its Phase 1b trial for Diabetic ...

and more »

BioSpace (press release) (blog)

Regeneron's Eylea Stumbles as FDA Issues CRL for New Dosing Label
BioSpace (press release) (blog)
Eylea has been approved as a treatment for wet AMD, macular edema following retinal vein occlusion and diabetic macular edema. In wet AMD, abnormal blood vessels leak fluid into the eye, ultimately causing damage and blindness. Affecting more than 20 ...
Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular ...PR Newswire (press release)

all 15 news articles »

Opthea Doses First Patient in Phase 2a Trial for OPT-302 in Diabetic Macular Edema
GlobeNewswire (press release)
MELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, has successfully dosed the first patient in the Phase 2a ...

and more »

Diabetic Macular Edema Drug Market Research by 2025: Top Players Like Alimera, Valeant, Novartis, Bayer, Allergan ...
Digital Journal
The latest report on the Global Diabetic Macular Edema Drug Market Report is the more professional in-depth of this market is providers the status and forecast, categorizes, market size (value & volume) by type, application, and region. This press ...


Nasdaq

Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD
Nasdaq
Eylea is approved in the United States, EU, Japan and other countries for the treatment of wet AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion and ...

and more »

More inflammation observed after aflibercept vs. ranibizumab injection
Healio
VANCOUVER, British Columbia — While eye pain outcomes were similar within a week of injection of either aflibercept or ranibizumab in patients with diabetic macular edema, more anterior chamber inflammation was seen in patients receiving aflibercept, ...


VIDEO: BOULEVARD trial advances molecule for treatment of DME
Healio
... he said validated the signal of RG7716 (Genentech/Roche) as a potential molecule for the treatment of diabetic macular edema and demonstrated the agent's “superiority to currently available therapeutics” as well as potential increased durability ...


Healio

VIDEO: More individualized treatment needed for DR, DME patients
Healio
... At the American Society of Retina Specialists meeting, Geeta A. Lalwani, MD, discusses applying results from the RIDE and RISE trials of anti-VEGF treatment to everyday, real-world treatment of diabetic retinopathy and diabetic macular edema.


MD Magazine

DRIL Presence Predictive of VA Improvement in Patients with Macular Edema, RVO
MD Magazine
“There was a definitive correlation with visual acuity in both diabetic macular edema and RVO,” Babiuch said. “While DRIL is not the biomarker, it is certainly useful in conjunction with other information, and should prompt continued treatment with ...


ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the ...
GlobeNewswire (press release)
Susan Schneider, MD, Chief Medical Officer of ThromboGenics nv, comments: "We are excited about the development of THR-317 for the potential treatment of diabetic macular edema. Topline results from this study show strong safety data as well as first ...


Business Wire (press release)

Verseon Interim Report Charts Progress of Development Programs as It Submits Phase I Protocol for Precision ...
Business Wire (press release)
Diabetic Macular Edema (DME). Verseon also detailed progress with its oral plasma kallikrein inhibitors for the treatment of diabetic macular edema (DME). These small-molecule drug candidates are suitable for oral dosing and could replace or complement ...

and more »

EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality
Nasdaq
ILUVIEN® (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema, licensed to Alimera Sciences, Inc., is currently sold directly in the U.S. and several EU countries. Retisert® (fluocinolone acetonide intravitreal ...

and more »

Medscape

Compliance in the Management of Diabetic Retinopathy: The Reality and Risk of Loss to Follow-up
Medscape
Vision loss in nonproliferative DR is often secondary to vessel leakage, with consequent diabetic macular edema (DME). In proliferative DR (PDR), progressive ischemia leads to retinal neovascularization, which can be complicated by vitreous hemorrhage, ...


MedPage Today

New Drugs Show Promise in Retinopathy
MedPage Today
VANCOUVER -- A dual-target monoclonal antibody outperformed anti-VEGF therapy in patients with diabetic macular edema (DME), according to data reported here. Among patients with no prior anti-VEGF therapy, the bispecific antibody RG7716 led to a ...


Diabetic Macular Edema Drug Market Capacity, Production, Share, Revenue Analysis with Forecast to 2025
ittechherald.com
Diabetic Macular Edema Drug Market research report reveals the effective ways to increase sale of Diabetic Macular Edema Drug in global and regional market. Diabetic Macular Edema Drug Market research is conducted for Intravitreal Injections ...

and more »

MedPage Today

Laser, Anti-VEGF Therapy Similar for DME
MedPage Today
VANCOUVER -- Patients with proliferative diabetic retinopathy (PDR) had similar 5-year vision outcomes when treated with intravitreal ranibizumab (Lucentis) or panretinal photocoagulation (PRP), a randomized study showed. Both treatments led to mean ...


thebusinesstactics.com

2018-2027 Diabetic Macular Edema Market Key strengths, Detailed Overview, Scope, Trendsand Industry Analysis ...
thebusinesstactics.com
Diabetic Macular Edema – Epidemiology Market Forecast, 2027 report provides a comprehensive analysis of the Diabetic Macular Edema epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.
Global Diabetic Macular Edema (DME) Market Growth Prospects, Scope and Forecasts Report to 2027trueindustrynews.com

all 6 news articles »

Alimera Sciences (ALIM) Given a $3.00 Price Target at HC ...
Fairfield Current
HC Wainwright set a $3.00 price objective on Alimera Sciences (NASDAQ:ALIM) in a research report sent to investors on Tuesday, July 31st. The brokerage ...
Invesco DWA Consumer Staples Mom ETF (PSL) Is At $71.21 Formed Wedge; Alimera Sciences (ALIM) Sentiment Is 1.5The Cardinal Weekly (press release)

all 3 news articles »

Chronicle India

Diabetic Macular Edema (DME) Market: Overview, Segmentation, Risk & Burden Industry Trend Forecast 2018 to 2027
Chronicle India
Diabetic Macular Edema (DME) – Market Insight, Epidemiology and Market Forecast – 2027” report provides a detailed analysis of the Diabetic Macular Edema (DME) epidemiology and market outlook for the 7MM. Markets Covered. United States.

and more »

Diabetic Macular Edema (DME) Market Therapies, Epidemiology, Pipeline Analysis, Trends and Major Depressive ...
The Newsman
Diabetic Macular Edema (DME) Market Epidemiology Report 2018 aims to fulfill the needs of the clients looking for a fresh outlook towards the Diabetic Macular Edema (DME) Market or fill in the knowledge gaps with the data available in the report.


Nasdaq

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
Nasdaq
Eylea is approved in the United States, EU, Japan and other countries for the treatment of neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular ...
Intl Fcstone Inc. Buys Shares of 674 Regeneron Pharmaceuticals Inc (REGN)Fairfield Current

all 14 news articles »

MedPage Today

Benefits with Early Treatment of Diabetic Retinopathy
MedPage Today
"But other points in the transition can be more ambiguous: Non-center involved DME [diabetic macular edema], center-involved DME without visual acuity loss, and non-high-risk proliferative diabetic retinopathy all allow room for debate. What about ...

» Load more